Contact
searchSearch
HMP Global

Advertisement

Advertisement

ADVERTISEMENT

John Allan, MD
Conference Coverage
Novel Updates in the Chronic Lymphocytic Leukemia Treatment Landscape
03/20/2024

Featuring John Allan, MD

Featuring John Allan, MD
At the Lymphoma, Leukemia & Myeloma Congress in New York, John Allan, MD, discusses novel updates in the chronic lymphocytic leukemia treatment landscape, highlighting studies that focused on BTK inhibitor combination treatments.
At the Lymphoma, Leukemia & Myeloma Congress in New York, John Allan, MD, discusses novel updates in the chronic lymphocytic leukemia treatment landscape, highlighting studies that focused on BTK inhibitor combination treatments.
At the Lymphoma, Leukemia &...
03/20/2024
Lymphoma, Leukemia & Myeloma Network
Jennifer Amengual, MD, Columbia University
Conference Coverage
Exploring Treatment Strategies for Elderly Patients With Aggressive Lymphoma Ineligible for CAR T-Cell Therapy
03/11/2024

Featuring Jennifer Amengual, MD

Featuring Jennifer Amengual, MD ...
At the Lymphoma, Leukemia & Myeloma Congress in New York, Jennifer Amengual, MD, discusses new approvals and treatment strategies for older patients with aggressive lymphoma who are ineligible for CAR T-cell therapy.
At the Lymphoma, Leukemia & Myeloma Congress in New York, Jennifer Amengual, MD, discusses new approvals and treatment strategies for older patients with aggressive lymphoma who are ineligible for CAR T-cell therapy.
At the Lymphoma, Leukemia &...
03/11/2024
Lymphoma, Leukemia & Myeloma Network
Jia Ruan, MD, PhD
Conference Coverage
Evaluating Chemo-Free Novel Agent Combination Therapies for Mantle Cell Lymphoma
03/01/2024

Featuring Jia Ruan, MD, PhD

Featuring Jia Ruan, MD, PhD
At the Lymphoma, Leukemia & Myeloma Congress, Jia Ruan, MD, PhD, discusses the introduction of chemotherapy-free novel agents for the treatment of patients with mantle cell lymphoma.
At the Lymphoma, Leukemia & Myeloma Congress, Jia Ruan, MD, PhD, discusses the introduction of chemotherapy-free novel agents for the treatment of patients with mantle cell lymphoma.
At the Lymphoma, Leukemia &...
03/01/2024
Lymphoma, Leukemia & Myeloma Network
Jia Ruan, MD, PhD
Conference Coverage
Use of BTK Inhibitors in the First-Line Mantle Cell Lymphoma Treatment Landscape
03/01/2024

Featuring Jia Ruan, MD, PhD

Featuring Jia Ruan, MD, PhD
At the Lymphoma, Leukemia & Myeloma Congress, Jia Ruan, MD, PhD, provides insight into the use of BTK inhibitors in the frontline mantle cell lymphoma treatment space.
At the Lymphoma, Leukemia & Myeloma Congress, Jia Ruan, MD, PhD, provides insight into the use of BTK inhibitors in the frontline mantle cell lymphoma treatment space.
At the Lymphoma, Leukemia &...
03/01/2024
Lymphoma, Leukemia & Myeloma Network
Jia Ruan, MD, PhD
Conference Coverage
Advances in Chemoimmunotherapy for Frontline Mantle Cell Lymphoma Treatment
03/01/2024

Featuring Jia Ruan, MD, PhD

Featuring Jia Ruan, MD, PhD
At the Lymphoma, Leukemia & Myeloma Congress, Jia Ruan, MD, PhD, discusses advances in chemoimmunotherapy for the first-line treatment of patients with mantle cell lymphoma.
At the Lymphoma, Leukemia & Myeloma Congress, Jia Ruan, MD, PhD, discusses advances in chemoimmunotherapy for the first-line treatment of patients with mantle cell lymphoma.
At the Lymphoma, Leukemia &...
03/01/2024
Lymphoma, Leukemia & Myeloma Network
Nicole Lamanna, MD
Conference Coverage
Exploring Potential Options for Treating Patients With Chronic Lymphocytic Leukemia With Pirtobrutinib
02/29/2024

Featuring Nicole Lamanna, MD

Featuring Nicole Lamanna, MD
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Nicole Lamanna, MD, discusses the potential for the use of non-covalent BTK inhibitor pirtobrutinib in treatment regimens for patients with chronic lymphocytic leukemia.
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Nicole Lamanna, MD, discusses the potential for the use of non-covalent BTK inhibitor pirtobrutinib in treatment regimens for patients with chronic lymphocytic leukemia.
At the Lymphoma, Leukemia &...
02/29/2024
Lymphoma, Leukemia & Myeloma Network
Neil Kay, MD, Mayo Clinic
Conference Coverage
Treatment Strategies for Patients With Double Refractory Chronic Lymphocytic Leukemia
02/27/2024

Featuring Neil E. Kay, MD

Featuring Neil E. Kay, MD
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Neil E. Kay, MD, discusses the pathobiology and management of double refractory CLL.
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Neil E. Kay, MD, discusses the pathobiology and management of double refractory CLL.
At the Lymphoma, Leukemia &...
02/27/2024
Lymphoma, Leukemia & Myeloma Network
Ajai Chari, MD
Conference Coverage
Optimal Use of Bispecific Antibodies for Multiple Myeloma Treatment
02/23/2024

Featuring Ajai Chari, MD

Featuring Ajai Chari, MD
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Ajai Chari, MD, University of California – San Francisco, San Francisco, California, discusses the role of bispecific antibodies in the treatment of patients with multiple...
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Ajai Chari, MD, University of California – San Francisco, San Francisco, California, discusses the role of bispecific antibodies in the treatment of patients with multiple...
At the Lymphoma, Leukemia &...
02/23/2024
Lymphoma, Leukemia & Myeloma Network
Ajai Chari, MD
Conference Coverage
Evaluating the Potential Value of MRD as a Predictive Variable for Multiple Myeloma
02/23/2024

Featuring Ajai Chari, MD

Featuring Ajai Chari, MD
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Ajai Chari, MD, evaluates the potential value of measurable residual disease as a predictive variable for multiple myeloma.
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Ajai Chari, MD, evaluates the potential value of measurable residual disease as a predictive variable for multiple myeloma.
At the Lymphoma, Leukemia &...
02/23/2024
Lymphoma, Leukemia & Myeloma Network
Ajai Chari, MD
Conference Coverage
Role of CD38 Monoclonal Antibodies and Bispecific Antibodies in Treating Multiple Myeloma
02/23/2024

Featuring Ajai Chari, MD

Featuring Ajai Chari, MD
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Ajai Chari, MD, shares his insights on the role of CD38 monoclonal antibodies and bispecific antibodies for the treatment of patients with multiple myeloma.
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Ajai Chari, MD, shares his insights on the role of CD38 monoclonal antibodies and bispecific antibodies for the treatment of patients with multiple myeloma.
At the Lymphoma, Leukemia &...
02/23/2024
Lymphoma, Leukemia & Myeloma Network
Michael R Green, PhD, The University of Texas MD Anderson Cancer Center, Houston, Texas
Conference Coverage
Emerging Role of Epigenetic Therapies in Follicular Lymphoma and DLBCL Treatment
02/15/2024

Featuring Michael R Green, PhD

Featuring Michael R Green, PhD ...
At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, New York, Michael Green, PhD, discusses the role of epigenetic therapies in treating lymphoma.
At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, New York, Michael Green, PhD, discusses the role of epigenetic therapies in treating lymphoma.
At the 2023 Lymphoma, Leukemia &...
02/15/2024
Lymphoma, Leukemia & Myeloma Network
Suzanne Lentszch, MD, PhD
Videos
Strategies for Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
02/13/2024

Featuring Suzanne Lentszch, MD, PhD

Featuring Suzanne Lentszch, MD, PhD ...
At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, New York, Suzanne Lentszch, MD, PhD, discusses the management of high-risk, newly diagnosed multiple myeloma.
At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, New York, Suzanne Lentszch, MD, PhD, discusses the management of high-risk, newly diagnosed multiple myeloma.
At the 2023 Lymphoma, Leukemia &...
02/13/2024
Lymphoma, Leukemia & Myeloma Network
Asher Chanan-Khan, MD
Conference Coverage
Benefits of BCL-2 Targeting Treatment for Patients With Chronic Lymphocytic Leukemia
01/29/2024

Featuring Asher Chanan-Khan, MD

Featuring Asher Chanan-Khan, MD ...
At the 2023 Lymphoma, Leukemia & Myeloma Congress, Asher Chanan-Khan, MD, argued in favor of treatments targeting BCL-2 for patients with chronic lymphocytic leukemia (CLL). 
At the 2023 Lymphoma, Leukemia & Myeloma Congress, Asher Chanan-Khan, MD, argued in favor of treatments targeting BCL-2 for patients with chronic lymphocytic leukemia (CLL). 
At the 2023 Lymphoma, Leukemia &...
01/29/2024
Lymphoma, Leukemia & Myeloma Network
Javier Pinilla-Ibarz, MD, PhD
Conference Coverage
Utilizing BTK Inhibitors to Treat Patients With Chronic Lymphocytic Leukemia
01/29/2024

Featuring Javier Pinilla-Ibarz, MD, PhD

Featuring Javier Pinilla-Ibarz, MD, P...
During the 2023 Lymphoma, Leukemia & Myeloma Congress, Javier Pinilla-Ibarz, MD, PhD, debated that BTK inhibitors are the preferred treatment regimen for patients with CLL.
During the 2023 Lymphoma, Leukemia & Myeloma Congress, Javier Pinilla-Ibarz, MD, PhD, debated that BTK inhibitors are the preferred treatment regimen for patients with CLL.
During the 2023 Lymphoma,...
01/29/2024
Lymphoma, Leukemia & Myeloma Network
Adriana Rossi, MD, Mount Sinai
Conference Coverage
CAR-T Cell Therapy vs Stem Cell Transplant for the Treatment of Patients With Multiple Myeloma
01/24/2024

Featuring Adriana Rossi, MD

Featuring Adriana Rossi, MD
During a debate at the 2023 Lymphoma, Leukemia & Myeloma Congress, Adriana Rossi, MD, discussed whether CAR-T therapy is more beneficial than stem cell transplant in treatment regimens among patients with multiple myeloma.
During a debate at the 2023 Lymphoma, Leukemia & Myeloma Congress, Adriana Rossi, MD, discussed whether CAR-T therapy is more beneficial than stem cell transplant in treatment regimens among patients with multiple myeloma.
During a debate at the 2023...
01/24/2024
Lymphoma, Leukemia & Myeloma Network
Dan Vogl, MD, University of Pennsylvania
Conference Coverage
Evaluating Bispecific T-Cell Engagers for the Treatment of Patients With Multiple Myeloma
01/23/2024

Featuring Dan Vogl, MD

Featuring Dan Vogl, MD
During the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Dan Vogl, MD, discusses the optimal use of newly available bispecific T-cell engagers and other targets for multiple myeloma treatment.
During the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Dan Vogl, MD, discusses the optimal use of newly available bispecific T-cell engagers and other targets for multiple myeloma treatment.
During the 2023 Lymphoma,...
01/23/2024
Lymphoma, Leukemia & Myeloma Network
Faith E. Davies, MD, Perlmutter Cancer Center
Conference Coverage
Choosing a Treatment Strategy for Patients With Early Relapsed Multiple Myeloma
01/22/2024

Featuring Faith E. Davies, MD

Featuring Faith E. Davies, MD
During the 2023 Lymphoma, Leukemia & Myeloma Congress, Faith E Davies, MD, discussed current treatment options for patients with early relapsed multiple myeloma.
During the 2023 Lymphoma, Leukemia & Myeloma Congress, Faith E Davies, MD, discussed current treatment options for patients with early relapsed multiple myeloma.
During the 2023 Lymphoma,...
01/22/2024
Lymphoma, Leukemia & Myeloma Network
Joseph Mikhael, MD, City of Hope Cancer Center
Conference Coverage
Strategies for Treating Patients With Multiply Relapsed Multiple Myeloma
01/19/2024

Featuring Joseph Mikhael, MD

Featuring Joseph Mikhael, MD
At the 2023 Lymphoma, Leukemia & Myeloma Congress, Joseph Mikhael, MD, discusses treatment regimens like CELMoDs and XP01 inhibitors for patients with multiply relapsed multiple myeloma.
At the 2023 Lymphoma, Leukemia & Myeloma Congress, Joseph Mikhael, MD, discusses treatment regimens like CELMoDs and XP01 inhibitors for patients with multiply relapsed multiple myeloma.
At the 2023 Lymphoma, Leukemia &...
01/19/2024
Lymphoma, Leukemia & Myeloma Network
Joseph Mikhael, MD, City of Hope Cancer Center
Conference Coverage
Benefits of MRD Testing for the Treatment of Patients With Multiple Myeloma
01/19/2024

Featuring Joseph Mikhael, MD 

Featuring Joseph Mikhael, MD 
At the 2023 Lymphoma, Leukemia & Myeloma Congress, Joseph Mikhael, MD, participated in a debate on the benefits of minimal residual disease testing in multiple myeloma treatment.
At the 2023 Lymphoma, Leukemia & Myeloma Congress, Joseph Mikhael, MD, participated in a debate on the benefits of minimal residual disease testing in multiple myeloma treatment.
At the 2023 Lymphoma, Leukemia &...
01/19/2024
Lymphoma, Leukemia & Myeloma Network
Elias Jabbour, MD, MD Anderson Cancer Center
Videos
Exploring Chemotherapy-Free Treatment for Patients With Philadelphia-Positive ALL
11/07/2023

Featuring Elias Jabbour, MD

Featuring Elias Jabbour, MD
At the 2023 Lymphoma, Leukemia & Myeloma Congress, Elias Jabbour, MD, discusses if chemotherapy can be eliminated from the treatment of Philadelphia-positive acute lymphoblastic leukemia.
At the 2023 Lymphoma, Leukemia & Myeloma Congress, Elias Jabbour, MD, discusses if chemotherapy can be eliminated from the treatment of Philadelphia-positive acute lymphoblastic leukemia.
At the 2023 Lymphoma, Leukemia &...
11/07/2023
Lymphoma, Leukemia & Myeloma Network
Ruben A. Mesa, MD, FACP, Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Videos
Novel Advances in the Treatment of Patients With Myelofibrosis
11/07/2023

Featuring Ruben A. Mesa, MD, FACP

Featuring Ruben A. Mesa, MD, FACP ...
At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Ruben A. Mesa, MD, FACP, discusses the latest updates in myelofibrosis treatment.
At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Ruben A. Mesa, MD, FACP, discusses the latest updates in myelofibrosis treatment.
At the 2023 Lymphoma, Leukemia &...
11/07/2023
Lymphoma, Leukemia & Myeloma Network
Gareth Morgan, MD, NYU Langone Medical Center
Videos
Role of Tumor Complexity and Microenvironment in the Development of Multiple Myeloma
11/02/2023

Featuring Gareth Morgan, MD

Featuring Gareth Morgan, MD
During the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Gareth Morgan, MD, examines the role of tumor complexity and microenvironment in the development of multiple myeloma.
During the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Gareth Morgan, MD, examines the role of tumor complexity and microenvironment in the development of multiple myeloma.
During the 2023 Lymphoma,...
11/02/2023
Lymphoma, Leukemia & Myeloma Network
Kenneth Anderson, MD, Dana-Farber Cancer Institute
Videos
New Targets on the Horizon for Multiple Myeloma Treatment
11/01/2023

Featuring Kenneth C. Anderson, MD

Featuring Kenneth C. Anderson, MD ...
At the 2023 Lymphoma, Leukemia & Myeloma Congress, Kenneth C. Anderson, MD, discussed existing and promising novel therapies for patients with multiple myeloma.
At the 2023 Lymphoma, Leukemia & Myeloma Congress, Kenneth C. Anderson, MD, discussed existing and promising novel therapies for patients with multiple myeloma.
At the 2023 Lymphoma, Leukemia &...
11/01/2023
Lymphoma, Leukemia & Myeloma Network
Eric Padron, MD, Moffitt Cancer Center
Videos
Updates on the Treatment of Patients With Chronic Myelomonocytic Leukemia
10/24/2023

Featuring Eric Padron, MD

Featuring Eric Padron, MD
During the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Eric Padron, MD, discusses updates regarding managing and treating chronic myelomonocytic leukemia.
During the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Eric Padron, MD, discusses updates regarding managing and treating chronic myelomonocytic leukemia.
During the 2023 Lymphoma,...
10/24/2023
Lymphoma, Leukemia & Myeloma Network
Julie Vose, MD
Videos
Advances in Treatment Options for Patients With T-Cell Lymphoma
10/24/2023

Featuring Julie Vose, MD

Featuring Julie Vose, MD
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Julie Vose, MD, discusses advances in improving outcomes for patients with peripheral T-cell lymphoma.
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Julie Vose, MD, discusses advances in improving outcomes for patients with peripheral T-cell lymphoma.
At the Lymphoma, Leukemia &...
10/24/2023
Lymphoma, Leukemia & Myeloma Network
Amer M. Zeidan, MBBS, MHS, Yale
Videos
Novel Treatment Options for Patients With Myelodysplastic Syndromes
10/24/2023

Featuring Amer Zeidan, MBBS, MHS 

Featuring Amer Zeidan, MBBS, MHS  ...
During the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Amer Zeidan, MBBS, MHS, provided insights into novel treatment updates for patients with high and low-risk MDS.
During the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Amer Zeidan, MBBS, MHS, provided insights into novel treatment updates for patients with high and low-risk MDS.
During the 2023 Lymphoma,...
10/24/2023
Oncology
Koen van Besien, MD
Videos
Benefit of AlloSCT for Patients With TP53 Mutations and Acute Myeloid Leukemia/Myelodysplastic Syndromes
03/13/2023
Koen W. van Besien, MD, recaps a debate in which he argued that patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) and TP53 mutations should undergo allogeneic stem cell transplantation.
Koen W. van Besien, MD, recaps a debate in which he argued that patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) and TP53 mutations should undergo allogeneic stem cell transplantation.
Koen W. van Besien, MD, recaps a...
03/13/2023
Oncology
Sundar Jagannath, MD, Mount Sinai
Videos
Bispecific Antibodies, CAR T-Cell Therapy, and BCMA-Directed Therapy for the Treatment of Multiple Myeloma With Curative Intent
02/23/2023
Sundar Jagannath, MD, provides an update on how immunotherapy and cellular therapy are changing treatment approaches for multiple myeloma.
Sundar Jagannath, MD, provides an update on how immunotherapy and cellular therapy are changing treatment approaches for multiple myeloma.
Sundar Jagannath, MD, provides...
02/23/2023
Oncology
Gail Roboz, MD, Weill Cornell Medicine
Videos
How to Handle Challenging Management Issues in AML
02/23/2023
Gail J. Roboz, MD, provides some key points to consider when handling challenging management issues in AML at the 2022 Lymphoma, Leukemia & Myeloma Congress in New York.
Gail J. Roboz, MD, provides some key points to consider when handling challenging management issues in AML at the 2022 Lymphoma, Leukemia & Myeloma Congress in New York.
Gail J. Roboz, MD, provides some...
02/23/2023
Oncology
Dan Vogl, MD, University of Pennsylvania
Videos
Bispecific T-Cell Engagers and Novel Approaches for the Treatment of Multiple Myeloma
02/23/2023
Dan Vogl, MD discusses options for bispecific T-Cell engagers when treating patients with multiple myeloma.
Dan Vogl, MD discusses options for bispecific T-Cell engagers when treating patients with multiple myeloma.
Dan Vogl, MD discusses options...
02/23/2023
Oncology
Faith Davies, MD
Videos
What Is the Optimal Combination for Patients With Multiple Myeloma in Early Relapse?
02/16/2023
Faith E. Davies, MD, provides an update on treatment options for patients with multiple myeloma in early relapse at the 2022 Lymphoma, Leukemia & Myeloma Congress in New York.
Faith E. Davies, MD, provides an update on treatment options for patients with multiple myeloma in early relapse at the 2022 Lymphoma, Leukemia & Myeloma Congress in New York.
Faith E. Davies, MD, provides an...
02/16/2023
Oncology
Pinkal Desai, MD
Videos
What Every Doctor Should Know About Clonal Hematopoiesis
02/15/2023
Pinkal Desai, MD, provides the latest updates on clonal hematopoiesis, highlighting what doctors should know about these aging-associated mutations.
Pinkal Desai, MD, provides the latest updates on clonal hematopoiesis, highlighting what doctors should know about these aging-associated mutations.
Pinkal Desai, MD, provides the...
02/15/2023
Oncology
Shaji Kumar, MD
Videos
Strategies for Treating Frail and Transplant-Ineligible Patients With Multiple Myeloma
01/26/2023
Shaji Kumar, MD, provides insight into approaches for treating frail and transplant-ineligible patients with multiple myeloma.
Shaji Kumar, MD, provides insight into approaches for treating frail and transplant-ineligible patients with multiple myeloma.
Shaji Kumar, MD, provides...
01/26/2023
Oncology
Javid Moslehi, MD
Videos
Considerations for Cardiovascular Adverse Events Associated With BTK Inhibitors for Patients With CLL
12/06/2022
Javid Moslehi, MD, discusses the cardiovascular risks associated with utilization of BTK inhibitors for patients with CLL and outlines best practices for managing these adverse events.
Javid Moslehi, MD, discusses the cardiovascular risks associated with utilization of BTK inhibitors for patients with CLL and outlines best practices for managing these adverse events.
Javid Moslehi, MD, discusses the...
12/06/2022
Oncology
Jia Ruan, MD
Videos
Novel Agents for Treatment of Patients With T-Cell Non-Hodgkin Lymphoma
12/01/2022
Jia Ruan, MD, highlights recent advancements in the treatment of patients with T-Cell non-Hodgkin lymphoma, presenting updated information on novel agents and ongoing clinical trials in this space.
Jia Ruan, MD, highlights recent advancements in the treatment of patients with T-Cell non-Hodgkin lymphoma, presenting updated information on novel agents and ongoing clinical trials in this space.
Jia Ruan, MD, highlights recent...
12/01/2022
Oncology
Julie Vose, MD
Videos
Approaches to Initial Therapy for Patients With Aggressive DLBCL
11/22/2022
Julie Vose, MD, provides insight into the latest approaches to initial therapy for patients with aggressive diffuse large B-cell lymphoma at the 2022 Lymphoma, Leukemia & Myeloma Congress in New York.
Julie Vose, MD, provides insight into the latest approaches to initial therapy for patients with aggressive diffuse large B-cell lymphoma at the 2022 Lymphoma, Leukemia & Myeloma Congress in New York.
Julie Vose, MD, provides insight...
11/22/2022
Oncology
Othman Al-Sawaf, MD
Videos
Role of Minimal Residual Disease in the Management of CLL: How Do We Use it and When?
11/15/2022
Othman Al-Sawaf, MD, provides insight into the best use of minimal residual disease in the management of patients with CLL, which he presented at the 2022 Lymphoma, Leukemia & Myeloma Congress.
Othman Al-Sawaf, MD, provides insight into the best use of minimal residual disease in the management of patients with CLL, which he presented at the 2022 Lymphoma, Leukemia & Myeloma Congress.
Othman Al-Sawaf, MD, provides...
11/15/2022
Oncology
Asher Chanan-Khan, MD
Videos
BTK Inhibitors vs BCL-2 Inhibitors as Frontline Therapy for Patients With CLL
11/14/2022
Asher Chanan-Khan, MD, argues in favor of BTK inhibitors over BCL-2 inhibitors for the frontline treatment of patients with CLL in a debate at the 2022 Lymphoma, Leukemia & Myeloma Congress.
Asher Chanan-Khan, MD, argues in favor of BTK inhibitors over BCL-2 inhibitors for the frontline treatment of patients with CLL in a debate at the 2022 Lymphoma, Leukemia & Myeloma Congress.
Asher Chanan-Khan, MD, argues in...
11/14/2022
Oncology
Jan Burger, MD
Videos
New and Emerging Targeted Agents for CLL: A Review of Available BTK Inhibitors
11/14/2022
Jan Burger, MD, discusses relevant genetic mutations in CLL which may influence treatment decisions and reviews safety and efficacy data on new and emerging targeted agents for these patients, focusing on BTK inhibitors.
Jan Burger, MD, discusses relevant genetic mutations in CLL which may influence treatment decisions and reviews safety and efficacy data on new and emerging targeted agents for these patients, focusing on BTK inhibitors.
Jan Burger, MD, discusses...
11/14/2022
Oncology
Sujit Sheth, MD
Videos
Novel Therapies for Non–Transfusion-Dependent and Transfusion-Dependent Thalassemia
11/03/2022
Sujit Sheth, MD, explains the pathophysiology of thalassemia and outlines novel therapies addressing unmet needs in this treatment landscape, including therapies with curative intent and those without curative intent.
Sujit Sheth, MD, explains the pathophysiology of thalassemia and outlines novel therapies addressing unmet needs in this treatment landscape, including therapies with curative intent and those without curative intent.
Sujit Sheth, MD, explains the...
11/03/2022
Oncology
Norman Latov, MD
Videos
Managing Peripheral Neuropathies Associated With Waldenström Macroglobulinemia
11/02/2022
Norman Latov, MD, outlines the types of peripheral neuropathies associated with Waldenström macroglobulinemia and IgM monoclonal gammopathies and discusses available therapies for managing these complications.
Norman Latov, MD, outlines the types of peripheral neuropathies associated with Waldenström macroglobulinemia and IgM monoclonal gammopathies and discusses available therapies for managing these complications.
Norman Latov, MD, outlines the...
11/02/2022
Oncology
Lorenzo Falchi, MD
Videos
Subcutaneous Epcoritamab With Rituximab and Lenalidomide for Relapsed/Refractory Follicular Lymphoma
11/02/2022
Lorenzo Falchi, MD, presents updated findings from a phase 1/2 trial exploring subcutaneous epcoritamab combined with rituximab and lenalidomide for patients with relapsed/refractory follicular lymphoma.
Lorenzo Falchi, MD, presents updated findings from a phase 1/2 trial exploring subcutaneous epcoritamab combined with rituximab and lenalidomide for patients with relapsed/refractory follicular lymphoma.
Lorenzo Falchi, MD, presents...
11/02/2022
Oncology
Morie Gertz, MD
Videos
Do All Patients Diagnosed With Waldenström Macroglobulinemia Require Immediate Intervention?
11/02/2022
Morie Gertz, MD, discusses options for managing patients with Waldenström macroglobulinemia, highlighting that not all patients diagnosed with the disease require immediate intervention.
Morie Gertz, MD, discusses options for managing patients with Waldenström macroglobulinemia, highlighting that not all patients diagnosed with the disease require immediate intervention.
Morie Gertz, MD, discusses...
11/02/2022
Oncology
Paul Richardson, MD
Videos
Novel CELMoD Agents for Multiple Myeloma: Iberdomide and Mezigdomide
10/21/2022
Paul Richardson, MD, provides an update on the treatment of multiple myeloma with novel CELMoD agents iberdomide and mezigdomide at the 2022 Lymphoma, Leukemia & Myeloma Congress in New York.
Paul Richardson, MD, provides an update on the treatment of multiple myeloma with novel CELMoD agents iberdomide and mezigdomide at the 2022 Lymphoma, Leukemia & Myeloma Congress in New York.
Paul Richardson, MD, provides an...
10/21/2022
Oncology
Keith Pratz, MD
Videos
Outpatient Combination Therapy in Patients With Newly Diagnosed AML
10/21/2022
Keith Pratz, MD, provides insights into navigating outpatient combination therapy in newly diagnosed acute myeloid leukemia at the 2022 Lymphoma, Leukemia & Myeloma Congress in New York.
Keith Pratz, MD, provides insights into navigating outpatient combination therapy in newly diagnosed acute myeloid leukemia at the 2022 Lymphoma, Leukemia & Myeloma Congress in New York.
Keith Pratz, MD, provides...
10/21/2022
Oncology
Michal Bar-Natan, MD
Videos
Novel Agents for Managing Patients With Relapsed ALL
10/19/2022
Michal Bar-Natan, MD, provides an update on the newest agents for management of relapsed ALL at the 2022 Lymphoma, Leukemia & Myeloma Congress in New York.
Michal Bar-Natan, MD, provides an update on the newest agents for management of relapsed ALL at the 2022 Lymphoma, Leukemia & Myeloma Congress in New York.
Michal Bar-Natan, MD, provides...
10/19/2022
Oncology
Elias Jabbour, MD, MD Anderson Cancer Center
Videos
Incorporation of Antibodies Into the Management of Upfront and Relapsed ALL
10/19/2022
Elias Jabbour, MD, provides an update on the incorporation of antibodies into the management of upfront and relapsed ALL.
Elias Jabbour, MD, provides an update on the incorporation of antibodies into the management of upfront and relapsed ALL.
Elias Jabbour, MD, provides an...
10/19/2022
Oncology
Ehab Atallah, MD
Videos
Management of CML: New Agents and Monitoring for MRD
10/19/2022
Ehab Atallah, MD, provides an update on the management of patients with CML, highlighting new available agents and the role of monitoring for MRD.
Ehab Atallah, MD, provides an update on the management of patients with CML, highlighting new available agents and the role of monitoring for MRD.
Ehab Atallah, MD, provides an...
10/19/2022
Oncology
Dr Paul
Videos
Dr Paul Discusses Magrolimab Combinations in Patients With R/R MM
11/29/2021
Barry Paul, MD, discusses a phase 2 multi-arm study of magrolimab combinations in patients with R/R MM. These data were presented at the 2021 LL&M Congress.
Barry Paul, MD, discusses a phase 2 multi-arm study of magrolimab combinations in patients with R/R MM. These data were presented at the 2021 LL&M Congress.
Barry Paul, MD, discusses a...
11/29/2021
Oncology
Dr Lee
Videos
Dr Lee Highlights the Treatment Landscape for Patients With MDS, AML
11/29/2021
Sangmin Lee, MD, highlights the current treatment landscape for patients with MDS, including novel therapies that are in development in combination with hypomethylating agents.
Sangmin Lee, MD, highlights the current treatment landscape for patients with MDS, including novel therapies that are in development in combination with hypomethylating agents.
Sangmin Lee, MD, highlights the...
11/29/2021
Oncology
Dr Wang
Videos
Live CLL Cells Inside Bone Marrow Fibroblasts May Have Implication in Drug Resistance
11/29/2021
Lynn Wang, MD, PhD, FCAP, discusses live CLL cells inside the bone marrow fibroblasts and their implication in drug resistance. These data were presented at the 2021 LL&M Congress.
Lynn Wang, MD, PhD, FCAP, discusses live CLL cells inside the bone marrow fibroblasts and their implication in drug resistance. These data were presented at the 2021 LL&M Congress.
Lynn Wang, MD, PhD, FCAP,...
11/29/2021
Oncology
Dr Cheson
Videos
Dr Cheson Discusses Anti-CD20 Monoclonal Antibodies in Patients With CLL
11/23/2021
Bruce Cheson, MD, FACP, FAAAS, FASCO, discusses anti-CD20 monoclonal antibodies for the management of patients with CLL; these data were presented at the virtual LL&M Congress.
Bruce Cheson, MD, FACP, FAAAS, FASCO, discusses anti-CD20 monoclonal antibodies for the management of patients with CLL; these data were presented at the virtual LL&M Congress.
Bruce Cheson, MD, FACP, FAAAS,...
11/23/2021
Oncology
Test Your Knowledge
Quiz: What is the Most Common Type of Lymphoma?
11/17/2021
There are a number of different types of lymphomas. Which is the most common?
There are a number of different types of lymphomas. Which is the most common?
There are a number of different...
11/17/2021
Oncology
Test Your Knowledge
Quiz: Does Targeting CD30 Lead to Improved Outcomes in PTCL?
11/12/2021
True or false: Targeting CD30 with an antibody drug conjugate or brentuximab bedouin together with chemotherapy leads to improved outcomes and survival in patients with CD30+ PTCL.
True or false: Targeting CD30 with an antibody drug conjugate or brentuximab bedouin together with chemotherapy leads to improved outcomes and survival in patients with CD30+ PTCL.
True or false: Targeting CD30...
11/12/2021
Oncology
Dr Leonard
Videos
John Leonard, MD, Discusses the Lymphoma Treatment Landscape
11/04/2021
Dr Leonard discusses the complex landscape and management of patients with lymphoma, including the use of monsunetuzumab therapy.
Dr Leonard discusses the complex landscape and management of patients with lymphoma, including the use of monsunetuzumab therapy.
Dr Leonard discusses the complex...
11/04/2021
Oncology
Dr Ruan
Videos
Jia Ruan, MD, PhD, Discusses the Current Treatment Landscape for T-Cell Lymphoma
11/01/2021
Dr Jia Ruan, discusses the current treatment landscape for patients with T-cell lymphomas.
Dr Jia Ruan, discusses the current treatment landscape for patients with T-cell lymphomas.
Dr Jia Ruan, discusses the...
11/01/2021
Oncology
Dr Choi
Interview
Dr Choi Discusses How To Best Sequence Regimens for Patients With CLL
10/25/2021
Michael Choi, MD, discusses how to best sequence regimens in the management of patients with CLL. This data was presented at the virtual 2021 LL&M Congress.
Michael Choi, MD, discusses how to best sequence regimens in the management of patients with CLL. This data was presented at the virtual 2021 LL&M Congress.
Michael Choi, MD, discusses how...
10/25/2021
Oncology
Dr Danilov
Interview
Dr Danilov Talks Clonal Dynamics and Venetoclax Resistance in CLL
10/22/2021
Alexey Danilov, MD, PhD, discusses clonal dynamics from the phase 3 CLL14 trial and mechanisms of resistance with venetoclax in patients with CLL at the 2021 virtual LL&M Congress.
Alexey Danilov, MD, PhD, discusses clonal dynamics from the phase 3 CLL14 trial and mechanisms of resistance with venetoclax in patients with CLL at the 2021 virtual LL&M Congress.
Alexey Danilov, MD, PhD,...
10/22/2021
Oncology
Dr Mailankody
Interview
Dr Mailankody Discusses When and How to Use CAR-T Therapy for MM
10/22/2021
During the LL&M Congress, Sham Mailankody, MBBS, discusses when and how to use CAR-T cell therapy for MM.
During the LL&M Congress, Sham Mailankody, MBBS, discusses when and how to use CAR-T cell therapy for MM.
During the LL&M Congress, Sham...
10/22/2021
Oncology
Dr Usmani
Interview
Dr Usmani Discusses Methods for Managing Patients With Newly Diagnosed MM
10/21/2021
At the 2021 virtual LL&M Congress, Saad Z. Usmani, MD, MBA, FACP, presents on the therapeutic benefits and methods for management of transplant-ineligible, elderly patients with newly diagnosed MM.
At the 2021 virtual LL&M Congress, Saad Z. Usmani, MD, MBA, FACP, presents on the therapeutic benefits and methods for management of transplant-ineligible, elderly patients with newly diagnosed MM.
At the 2021 virtual LL&M...
10/21/2021
Oncology
Dr Kaufman
Interview
Dr Kaufman Discusses the Role of Maintenance Therapy in MM
10/21/2021
Jonathan L. Kaufman, MD, discusses the role of maintenance therapy in MM; the data of which were presented at the 2021 virtual LL&M Congress.
Jonathan L. Kaufman, MD, discusses the role of maintenance therapy in MM; the data of which were presented at the 2021 virtual LL&M Congress.
Jonathan L. Kaufman, MD,...
10/21/2021
Oncology
Dr Pettit
Interview
Dr Pettit Highlights Whether Low-Risk MDS Is Really Low Risk
10/20/2021
Kristen Pettit, MD, discusses MDS and highlights if low-risk MDS is really low risk. These data were presented at the virtual 2021 LL&M Congress.
Kristen Pettit, MD, discusses MDS and highlights if low-risk MDS is really low risk. These data were presented at the virtual 2021 LL&M Congress.
Kristen Pettit, MD, discusses...
10/20/2021
Oncology
Dr Ruan
Videos
Dr Ruan Highlights Hot Topics in the Lymphoma Space
10/10/2021
Jia Ruan, MD, PhD, highlights various hot topics being discussed in the lymphoma space.
Jia Ruan, MD, PhD, highlights various hot topics being discussed in the lymphoma space.
Jia Ruan, MD, PhD, highlights...
10/10/2021
Oncology
Dr Evans Discusses Updates in the Treatment of Patients With FL
Videos
Dr Evans Discusses Updates in the Treatment of Patients With FL
01/29/2021
In this video, Andrew Evens, DO, MSc, FACP, discusses a couple of key publications and data sets in the field of EZH2-mutated and EZH2 wild type FL.
In this video, Andrew Evens, DO, MSc, FACP, discusses a couple of key publications and data sets in the field of EZH2-mutated and EZH2 wild type FL.
In this video, Andrew Evens, DO,...
01/29/2021
Oncology
Dr Cook Talks Advancements in the Treatment of FL With EZH2 Inhibitors
Videos
Dr Cook Talks Advancements in the Treatment of FL With EZH2 Inhibitors
11/01/2020
Perry C. Cook, MD, talks about progress made in the use of EZH2 inhibitors for the treatment of patients with FL.
Perry C. Cook, MD, talks about progress made in the use of EZH2 inhibitors for the treatment of patients with FL.
Perry C. Cook, MD, talks about...
11/01/2020
Oncology
Noopur Raje, MD, Talks Anti-BCMA CAR-T Therapy for Relapsed/Refractory MM
Podcasts
Noopur Raje, MD, Talks Anti-BCMA CAR-T Therapy for Relapsed/Refractory MM
10/28/2020
In this podcast, Dr Raje discusses the clinical significance of anti-BCMA CAR-T therapy with bb2121 in patients with relapsed or refractory MM.
In this podcast, Dr Raje discusses the clinical significance of anti-BCMA CAR-T therapy with bb2121 in patients with relapsed or refractory MM.
In this podcast, Dr Raje...
10/28/2020
Oncology
Tazemetostat Therapy for Patients With Relapsed/Refractory FL
Videos
Tazemetostat Therapy for Patients With Relapsed/Refractory FL
10/28/2020
Perry C. Cook, MD, discusses the use of tazemetostat for the treatment of patients with relapsed/refractory FL.
Perry C. Cook, MD, discusses the use of tazemetostat for the treatment of patients with relapsed/refractory FL.
Perry C. Cook, MD, discusses the...
10/28/2020
Oncology
Hot Topics in AML from the Virtual 2020 Lymphoma, Leukemia and Myeloma Congress
Videos
Hot Topics in AML from the Virtual 2020 Lymphoma, Leukemia and Myeloma Congress
10/24/2020
Gail J. Roboz, MD, summarizes the sessions she presented and debates she took part in at this year's congress.
Gail J. Roboz, MD, summarizes the sessions she presented and debates she took part in at this year's congress.
Gail J. Roboz, MD, summarizes...
10/24/2020
Oncology
Conference Insider
Triplet Combo Yields Significant Efficacy in Certain Patients With Lenalidomide-Refractory MM
10/23/2020
A triplet combo therapy comprising carfilzomib, lenalidomide, and dexamethasone has shown significant efficacy in patients with relapsed or refractory MM.
A triplet combo therapy comprising carfilzomib, lenalidomide, and dexamethasone has shown significant efficacy in patients with relapsed or refractory MM.
A triplet combo therapy...
10/23/2020
Oncology
BCMA-Directed CAR-T Therapy Shows Promise in Pretreated MM
Podcasts
BCMA-Directed CAR-T Therapy Shows Promise in Pretreated MM
10/22/2020
Jesus Berdeja, MD, discusses the results of the CARTITUDE-1 trial exploring BCMA-directed CAR-T therapy in relapsed/refractory MM.
Jesus Berdeja, MD, discusses the results of the CARTITUDE-1 trial exploring BCMA-directed CAR-T therapy in relapsed/refractory MM.
Jesus Berdeja, MD, discusses the...
10/22/2020
Oncology
New Approaches in the Treatment of Patients With Low-Risk MDS
Conference Insider
New Approaches in the Treatment of Patients With Low-Risk MDS
10/21/2020
Sangmin Lee, MD, provides an overview of novel strategies for patients with low-risk MDS.
Sangmin Lee, MD, provides an overview of novel strategies for patients with low-risk MDS.
Sangmin Lee, MD, provides an...
10/21/2020
Oncology
Conference Insider
Diffusion-Weighted MRI Could Guide Need for BMB in Newly Diagnosed Myeloma
10/21/2020
Researchers have observed a moderate positive correlation between sacral ala bone marrow ADC and plasma cell burden on BMB in patients with newly diagnosed myeloma.
Researchers have observed a moderate positive correlation between sacral ala bone marrow ADC and plasma cell burden on BMB in patients with newly diagnosed myeloma.
Researchers have observed a...
10/21/2020
Oncology
Navigating the MM Treatment Landscape
Podcasts
Navigating the MM Treatment Landscape
10/20/2020
Natalie S. Callander, MD, discusses individualized treatment approaches for patients with relapsed or refractory MM.
Natalie S. Callander, MD, discusses individualized treatment approaches for patients with relapsed or refractory MM.
Natalie S. Callander, MD,...
10/20/2020
Oncology
James Bussel, MD, Shares Highlights from the Pre-LLM Congress Non-Malignant Day
Videos
James Bussel, MD, Shares Highlights from the Pre-LLM Congress Non-Malignant Day
10/20/2020
Dr Bussel shares insight on hot topics, highlights, and key takeaways from this year's virtual event.
Dr Bussel shares insight on hot topics, highlights, and key takeaways from this year's virtual event.
Dr Bussel shares insight on hot...
10/20/2020
Oncology
Podcasts
Dr Leonard Shares Highlights to Expect at the 2020 Lymphoma, Leukemia & Myeloma Congress
10/19/2020
John Leonard, MD, discusses what to expect at the virtual 2020 Lymphoma, Leukemia & Myeloma Congress taking place October 21-24, 2020.
John Leonard, MD, discusses what to expect at the virtual 2020 Lymphoma, Leukemia & Myeloma Congress taking place October 21-24, 2020.
John Leonard, MD, discusses what...
10/19/2020
Oncology
What to Expect at the Non-Malignant Hematology Workshop at Lymphoma, Leukemia & Myeloma Congress
Podcasts
What to Expect at the Non-Malignant Hematology Workshop at Lymphoma, Leukemia & Myeloma Congress
08/24/2020
James B. Bussel, MD, gives an overview of what to expect at the brand new Non-Malignant Hematology Workshop and how the content is critical for hematology and oncology practice.
James B. Bussel, MD, gives an overview of what to expect at the brand new Non-Malignant Hematology Workshop and how the content is critical for hematology and oncology practice.
James B. Bussel, MD, gives an...
08/24/2020
Oncology
Efficacy and Safety of Current Treatment Options for HCL
Videos
Efficacy and Safety of Current Treatment Options for HCL
01/20/2020
Jacqueline Barrientos, MD, MS, discusses how the treatment landscape for hairy cell leukemia has evolved.
Jacqueline Barrientos, MD, MS, discusses how the treatment landscape for hairy cell leukemia has evolved.
Jacqueline Barrientos, MD, MS,...
01/20/2020
Oncology
Differences in Biology and Treatment of FL and MZL
Videos
Differences in Biology and Treatment of FL and MZL
01/20/2020
Thomas Habermann, MD, explains differences in the treatment approaches for follicular and marginal zone lymphomas.
Thomas Habermann, MD, explains differences in the treatment approaches for follicular and marginal zone lymphomas.
Thomas Habermann, MD, explains...
01/20/2020
Oncology
Updates in Diagnosing and Treating Peripheral T-Cell Lymphoma
Videos
Updates in Diagnosing and Treating Peripheral T-Cell Lymphoma
01/17/2020
Jia Ruan, MD, PhD, Weill Cornell Medicine, shares updates on the diagnosis and treatment of peripheral T-cell lymphoma.
Jia Ruan, MD, PhD, Weill Cornell Medicine, shares updates on the diagnosis and treatment of peripheral T-cell lymphoma.
Jia Ruan, MD, PhD, Weill Cornell...
01/17/2020
Oncology
Ibrutinib Plus Rituximab Yields Significant PFS Benefit Over FCR for CLL
Videos
Ibrutinib Plus Rituximab Yields Significant PFS Benefit Over FCR for CLL
01/12/2020
Neil Kay, MD, discusses results from the E1912 trial, which showed a significant PFS benefit with ibrutinib plus rituximab over standard FCR in CLL.
Neil Kay, MD, discusses results from the E1912 trial, which showed a significant PFS benefit with ibrutinib plus rituximab over standard FCR in CLL.
Neil Kay, MD, discusses results...
01/12/2020
Oncology
The Role of Observation in Follicular Lymphoma
Videos
The Role of Observation in Follicular Lymphoma
01/06/2020
Carla Casulo, MD, University of Rochester Medical Center, discusses the role of observation in the treatment landscape of follicular lymphoma.
Carla Casulo, MD, University of Rochester Medical Center, discusses the role of observation in the treatment landscape of follicular lymphoma.
Carla Casulo, MD, University of...
01/06/2020
Oncology
Deep Sequencing Impacts Treatment Landscape for MM
Videos
Deep Sequencing Impacts Treatment Landscape for MM
01/03/2020
Gareth Morgan, MD, PhD, discusses deep sequencing and how it is improving the treatment landscape for MM.
Gareth Morgan, MD, PhD, discusses deep sequencing and how it is improving the treatment landscape for MM.
Gareth Morgan, MD, PhD,...
01/03/2020
Oncology
Treatment Options for Advanced Stage Lymphoma
Videos
Treatment Options for Advanced Stage Lymphoma
01/03/2020
Joseph Connors, MD, discusses the best choices for treating patients with advanced stage lymphoma.
Joseph Connors, MD, discusses the best choices for treating patients with advanced stage lymphoma.
Joseph Connors, MD, discusses...
01/03/2020
Oncology
Videos
Should You Stop TKI Treatment for CML in Major Molecular Response?
12/23/2019
Sangmin Lee, MD, discusses whether or not you should stop TKI treatment in patients with CML in major molecular response.
Sangmin Lee, MD, discusses whether or not you should stop TKI treatment in patients with CML in major molecular response.
Sangmin Lee, MD, discusses...
12/23/2019
Oncology
Videos
Treatment Options for Patients With Mantle Cell Lymphoma
12/05/2019
Michael Williams, MD, discusses treatment approaches for a variety of patients with mantle cell lymphoma.
Michael Williams, MD, discusses treatment approaches for a variety of patients with mantle cell lymphoma.
Michael Williams, MD, discusses...
12/05/2019
Oncology
Videos
What is the Best Treatment Approach for Patients With MM Ineligible for Transplant?
11/13/2019
Vincent Rajkumar, MD, explains treatment approaches for patients with newly-diagnosed MM ineligible for transplant.
Vincent Rajkumar, MD, explains treatment approaches for patients with newly-diagnosed MM ineligible for transplant.
Vincent Rajkumar, MD, explains...
11/13/2019
Oncology
Videos
CAR T-Cell Therapy: Where Do We Stand in 2019?
11/13/2019
Thomas Kipps, MD, PhD, gives an update on the development of CAR T-cell therapy at the 2019 Lymphoma & Myeloma Congress.
Thomas Kipps, MD, PhD, gives an update on the development of CAR T-cell therapy at the 2019 Lymphoma & Myeloma Congress.
Thomas Kipps, MD, PhD, gives an...
11/13/2019
Oncology
Videos
Novel Agents for Treating Older Patients With CLL
11/13/2019
Jennifer Woyach, MD, discusses treatment options for older patients with CLL and why treating older patients differs from treating younger patients.
Jennifer Woyach, MD, discusses treatment options for older patients with CLL and why treating older patients differs from treating younger patients.
Jennifer Woyach, MD, discusses...
11/13/2019
Oncology
Videos
Managing Venetoclax Resistance in CLL
11/12/2019
Matthew S. Davids, MD, MMSc, discusses venetoclax resistance in CLL and how to manage patients resistant to the drug.
Matthew S. Davids, MD, MMSc, discusses venetoclax resistance in CLL and how to manage patients resistant to the drug.
Matthew S. Davids, MD, MMSc,...
11/12/2019
Oncology
Videos
Who Should Receive CAR T-Cell Therapy for DLBCL?
11/12/2019
Craig Sauter, MD, explains which patients should receive CAR T-cells for DLBCL.
Craig Sauter, MD, explains which patients should receive CAR T-cells for DLBCL.
Craig Sauter, MD, explains which...
11/12/2019
Oncology
Videos
Should Monoclonal Antibodies Be Used in the Front-Line Setting for MM?
11/12/2019
Ajai Chari, MD, explains whether anti‑CS1, anti‑CD38, and bispecifics, should be used in the frontline setting for multiple myeloma.
Ajai Chari, MD, explains whether anti‑CS1, anti‑CD38, and bispecifics, should be used in the frontline setting for multiple myeloma.
Ajai Chari, MD, explains whether...
11/12/2019
Oncology
Videos
Treating CLL That Progress With BTK Inhibitor Therapy
11/12/2019
Richard Furman, MD, explains how best to control CLL patients who progress on BTK inhibitor therapy.
Richard Furman, MD, explains how best to control CLL patients who progress on BTK inhibitor therapy.
Richard Furman, MD, explains how...
11/12/2019
Oncology
Videos
Indications for Transplant in Low/Intermediate Risk MDS
11/07/2019
Koen van Besien, MD, PhD, discusses data on the indications for transplant for patients with low and intermediate‑grade MDS.
Koen van Besien, MD, PhD, discusses data on the indications for transplant for patients with low and intermediate‑grade MDS.
Koen van Besien, MD, PhD,...
11/07/2019
Oncology
Videos
New Approaches to Treating Waldenström Macroglobulinemia
11/04/2019
Steven Treon, MD, PhD, FACP, FRCP, provided an update on the latest research in the treatment of Waldenström Macroglobulinemia.
Steven Treon, MD, PhD, FACP, FRCP, provided an update on the latest research in the treatment of Waldenström Macroglobulinemia.
Steven Treon, MD, PhD, FACP,...
11/04/2019
Oncology
Videos
What is the Role of P53 in Deciding a Treatment Approach for Relapsed MM?
11/01/2019
Shaji Kumar, MD, discussed the role of the P53 gene in deciding the best treatment approach for patients with relapsed MM.
Shaji Kumar, MD, discussed the role of the P53 gene in deciding the best treatment approach for patients with relapsed MM.
Shaji Kumar, MD, discussed the...
11/01/2019
Oncology
Videos
What is the Best Treatment Approach for Smoldering Myeloma?
10/25/2019
Joseph Mikhael, MD, MEd, FRCPC, explains the best treatment approach for patients with smoldering myeloma.
Joseph Mikhael, MD, MEd, FRCPC, explains the best treatment approach for patients with smoldering myeloma.
Joseph Mikhael, MD, MEd, FRCPC,...
10/25/2019
Oncology
Comparing Sequential Monotherapy With Combo Therapy in CLL
10/25/2019
John Allan, MD, shares important considerations for comparing sequential monotherapy with combination therapy in CLL.
John Allan, MD, shares important considerations for comparing sequential monotherapy with combination therapy in CLL.
John Allan, MD, shares important...
10/25/2019
Oncology
Videos
Immunotherapies in Multiple Myeloma
10/25/2019
David E. Avigan, MD discusses active immunotherapies for the treatment of multiple myeloma.
David E. Avigan, MD discusses active immunotherapies for the treatment of multiple myeloma.
David E. Avigan, MD discusses...
10/25/2019
Oncology
Videos
Novel Therapies in AML
10/24/2019
Gail Roboz, MD, summarizes her presentation about novel therapies in AML at the 2019 Lymphoma & Myeloma Congress.
Gail Roboz, MD, summarizes her presentation about novel therapies in AML at the 2019 Lymphoma & Myeloma Congress.
Gail Roboz, MD, summarizes her...
10/24/2019
Oncology
News
Management of Patients With Relapsed T-Cell ALL
10/23/2019
Pinkal Desai, MD, MPH, discusses the management of difficult cases of ALL, particularly relapsed T-cell disease.
Pinkal Desai, MD, MPH, discusses the management of difficult cases of ALL, particularly relapsed T-cell disease.
Pinkal Desai, MD, MPH, discusses...
10/23/2019
Oncology
Selecting, Switching, and Discontinuing First-Line TKIs in CML
10/23/2019
Dr Lee tells attendees of the Lymphoma & Myeloma Congress about current approaches to optimizing the care of patients with CML in the era of TKIs.
Dr Lee tells attendees of the Lymphoma & Myeloma Congress about current approaches to optimizing the care of patients with CML in the era of TKIs.
Dr Lee tells attendees of the...
10/23/2019
Oncology
Videos
Alternative Treatment Options for Older Patients With AML
10/23/2019
Sangmin Lee, MD, argued that venetoclax plus azacitidine, decitabine, and LDAC should not be the new standard care for older patients with AML.
Sangmin Lee, MD, argued that venetoclax plus azacitidine, decitabine, and LDAC should not be the new standard care for older patients with AML.
Sangmin Lee, MD, argued that...
10/23/2019
Oncology
Videos
Lymphoma & Myeloma Congress 2019: Chair Insights
08/13/2019
In this short video, 3 of the Lymphoma & Myeloma Congress Chairs share why their passion for the event is so strong.
In this short video, 3 of the Lymphoma & Myeloma Congress Chairs share why their passion for the event is so strong.
In this short video, 3 of the...
08/13/2019
Oncology
Videos
Genomic Testing and Tailored Therapies for Multiple Myeloma
12/13/2018
Joseph Mikhael, MD, MEd, FRCPC, spoke to Oncology Learning Network about genomic testing in multiple myeloma and how it can help clinicians personalize treatments for patients. He also shared his favorite analogy for using targeted therapy in...
Joseph Mikhael, MD, MEd, FRCPC, spoke to Oncology Learning Network about genomic testing in multiple myeloma and how it can help clinicians personalize treatments for patients. He also shared his favorite analogy for using targeted therapy in...
Joseph Mikhael, MD, MEd, FRCPC,...
12/13/2018
Oncology
Videos
Richard Furman, MD, Discusses Richter's Transformation and Emerging Therapies in CLL
11/08/2018
Dr Furman discusses disease progression with BTK inhibitor therapy, Richter's transformation, and emerging treatment options for CLL.
Dr Furman discusses disease progression with BTK inhibitor therapy, Richter's transformation, and emerging treatment options for CLL.
Dr Furman discusses disease...
11/08/2018
Oncology
Videos
Jonathon Cohen, MD, Discusses Treatment Options and Prognosis in MCL
11/08/2018
Dr Cohen discusses the available treatment options for patients with MCL, and describes methods for predicting patient response to specific therapies.
Dr Cohen discusses the available treatment options for patients with MCL, and describes methods for predicting patient response to specific therapies.
Dr Cohen discusses the available...
11/08/2018
Oncology
Improving Outcomes in CLL With a Prognostic Approach
10/20/2018
By preemptively looking for patients with CLL who are most likely to not respond to BTK inhibitor therapy, clinicians can improve outcomes in this population, according to Richard Furman, MD.
By preemptively looking for patients with CLL who are most likely to not respond to BTK inhibitor therapy, clinicians can improve outcomes in this population, according to Richard Furman, MD.
By preemptively looking for...
10/20/2018
Oncology
Venetoclax Promising in the Treatment of CLL
10/19/2018
At L&M 2018, Richard R. Furman, MD, discussed venetoclax in the treatment of patients with chronic lymphocytic leukemia.
At L&M 2018, Richard R. Furman, MD, discussed venetoclax in the treatment of patients with chronic lymphocytic leukemia.
At L&M 2018, Richard R. Furman,...
10/19/2018
Oncology
The Future Treatment Landscape for Relapsed and Refractory Myeloma
10/19/2018
Kenneth C. Anderson, MD, discussed the future of the treatment landscape for patients with relapsed and refractory myeloma.
Kenneth C. Anderson, MD, discussed the future of the treatment landscape for patients with relapsed and refractory myeloma.
Kenneth C. Anderson, MD,...
10/19/2018
Oncology
Multiple Genetic Drivers Key to Enhancing Individualized Therapy in Multiple Myeloma
10/18/2018
It is crucial to address the genetic drivers of both multiple myeloma and its environment when individualizing treatment, according to Joseph Mikhael, MD, MEd, FRCPC.
It is crucial to address the genetic drivers of both multiple myeloma and its environment when individualizing treatment, according to Joseph Mikhael, MD, MEd, FRCPC.
It is crucial to address the...
10/18/2018
Oncology
Benefits of Genome Sequencing in Multiple Myeloma
10/18/2018
DNA and RNA sequencing improve personalized treatment in multiple myeloma, and are feasible and effective for relapsed disease, explained Samir Parekh, MBBS.
DNA and RNA sequencing improve personalized treatment in multiple myeloma, and are feasible and effective for relapsed disease, explained Samir Parekh, MBBS.
DNA and RNA sequencing improve...
10/18/2018
Oncology
Therapies are Rapidly Evolving for Patients With Newly Diagnosed AML
10/17/2018
At the 2018 L&M congress, Gail Roboz, MD, discussed current therapy options for patients with newly diagnosed AML.
At the 2018 L&M congress, Gail Roboz, MD, discussed current therapy options for patients with newly diagnosed AML.
At the 2018 L&M congress, Gail...
10/17/2018
Oncology
MRD Testing a Crucial Component in Treatment of Patients With AML
10/17/2018
Clinicians should measure MRD in their patients with AML, because CR on its own is simply not enough, Gail J. Roboz, MD, asserted at the 2018 L&M congress.
Clinicians should measure MRD in their patients with AML, because CR on its own is simply not enough, Gail J. Roboz, MD, asserted at the 2018 L&M congress.
Clinicians should measure MRD in...
10/17/2018
Oncology
Notable Speakers Attending the 2018 Lymphoma & Myeloma Congress
10/12/2018
Leading experts in the hematology oncology space will be sharing their insights and presenting cutting-edge research at the 18th annual L&M Congress, October 17-20, 2018, in New York.
Leading experts in the hematology oncology space will be sharing their insights and presenting cutting-edge research at the 18th annual L&M Congress, October 17-20, 2018, in New York.
Leading experts in the...
10/12/2018
Oncology
Videos
Key Insights in Multiple Myeloma
02/27/2018
Drs Morton Coleman and Ruben Niesvizky summarize the key take-home points presented on multiple myeloma during Lymphoma & Myeloma 2016.
Drs Morton Coleman and Ruben Niesvizky summarize the key take-home points presented on multiple myeloma during Lymphoma & Myeloma 2016.
Drs Morton Coleman and Ruben...
02/27/2018
Oncology

Advertisement

About

For nearly 2 decades, the Lymphoma, Leukemia & Myeloma Congress (formerly the Lymphoma & Myeloma Congress) has been recognized around the world as the most respected forum for industry-leading hematologic research.

It’s where interdisciplinary specialists convene to explore the controversial and the complex, the emerging and the exciting, and discuss, debate, and discover along the way.

This program features 4 days of comprehensive learning as we analyze emerging data, discover innovative treatment methods, and get a glimpse into the future of lymphoma, myeloma, and leukemia disorders.

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use